Landfar Bio-medicine Co., Ltd (SHE:000504)
China · Delayed Price · Currency is CNY 8.11
+0.32 (4.11%)
Aug 4, 2026, 3:04 PM CST
Landfar Bio-medicine Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
| 2,676 | 2,954 | 2,756 | 3,614 | 3,627 | 5,795 | |
Market Cap Growth | -26.07% | 7.19% | -23.76% | -0.34% | -37.42% | 51.96% |
Enterprise Value | 2,815 | 2,941 | 2,522 | 3,679 | 3,774 | 6,136 |
Last Close Price | 8.11 | 8.95 | 8.35 | 11.60 | 11.64 | 18.60 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
PE Ratio | 61.60 | 102.46 | - | - | - | - |
PS Ratio | 5.22 | 7.10 | 20.50 | 26.42 | 18.10 | 37.00 |
PB Ratio | 7.25 | 8.26 | 9.77 | 11.86 | 45.23 | 52.53 |
P/TBV Ratio | 12.44 | 14.50 | 11.81 | 14.20 | 696.61 | 726.09 |
P/FCF Ratio | - | - | - | 119.05 | 24.27 | 77.13 |
P/OCF Ratio | - | - | 574.87 | 99.63 | 21.80 | 54.11 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.49 | 7.07 | 18.76 | 26.90 | 18.84 | 39.18 |
EV/EBITDA Ratio | 82.13 | 266.25 | - | - | - | - |
EV/EBIT Ratio | 106.45 | 450.27 | - | - | - | - |
EV/FCF Ratio | - | - | - | 121.19 | 25.26 | 81.67 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.95 | 0.96 | 0.09 | 0.67 | 2.95 | 2.83 |
Debt / EBITDA Ratio | 10.20 | 24.60 | - | - | - | - |
Debt / FCF Ratio | - | - | - | 6.72 | 1.58 | 4.16 |
Net Debt / Equity Ratio | 0.13 | -0.01 | -0.65 | -0.96 | 0.21 | 1.44 |
Net Debt / EBITDA Ratio | 1.47 | -0.50 | 14.37 | 8.70 | -1.65 | -8.62 |
Net Debt / FCF Ratio | -0.22 | 0.05 | 13.65 | -9.61 | 0.11 | 2.11 |
Asset Turnover | 0.63 | 0.52 | 0.20 | 0.21 | 0.33 | 0.26 |
Inventory Turnover | 11.69 | 12.32 | 2.00 | 5.92 | 9.64 | 3.62 |
Quick Ratio | 1.21 | 1.26 | 1.15 | 1.41 | 0.89 | 0.68 |
Current Ratio | 1.38 | 1.36 | 1.32 | 1.45 | 0.91 | 0.98 |
Return on Equity (ROE) | 11.07% | 5.65% | -8.16% | -24.31% | -30.93% | -27.04% |
Return on Assets (ROA) | 2.04% | 0.51% | -1.39% | -3.45% | -1.33% | -2.26% |
Return on Invested Capital (ROIC) | 6.60% | 2.66% | -27.62% | -66.71% | -7.06% | -7.22% |
Return on Capital Employed (ROCE) | 5.70% | 1.50% | -5.10% | -11.50% | -13.10% | -16.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.57% | 0.98% | -0.72% | -0.78% | -0.34% | -0.33% |
FCF Yield | -7.97% | -4.09% | -0.49% | 0.84% | 4.12% | 1.30% |
Payout Ratio | 7.19% | 8.20% | - | - | - | - |
Buyback Yield / Dilution | 3.31% | 3.16% | -5.67% | -0.51% | 2.30% | -17.27% |